The Leishmaniasis East Africa Platform (LEAP) was established to support the generation of scientific evidence for the development and distribution of new treatments for leishmaniasis in Eastern Africa.
To support its R&D activities on Chagas disease, DNDi launched the Chagas Clinical Research Platform (CCRP). The platform brings together partners, experts, and stakeholders to provide support for evaluation and development of new treatments for Chagas disease. The patient-centred platform aims to f...acilitate clinical research, provide a forum for technical discussions, develop a critical mass of expertise, and strengthen institutional research capacities. In addition, it identifies and reviews priority needs, works towards standardization of methodology to assess drug efficacy and reviews alternatives for using current approved drugs (new schemes, doses, combination) and special scenarios (resistance).
more
DNDi’s long-term goal for sleeping sickness, also known as human African trypanosomiasis (HAT), is to develop and register two new drugs that are effective against both Stage 1 and Stage 2 of the disease and both subspecies of the parasite, T.b. gambiense and T.b. rhodesiense. T.b. rhodesiense is ...an acute form of the disease, occurring primarily in Eastern and Southern Africa. Better treatments for T.b. rhodesiense sleeping sickness are urgently needed.
more
La leishmaniasis es una enfermedad tropical desatendida sensible
al clima, trasmitida por la picadura de insectos flebótomos y
se calcula que amenaza a mil millones de personas en todo el mundo.
Esta enfermedad altamente compleja se presenta de varias formas
clínicas, causadas por 20 especies ...del parásito Leishmania.
more
A summary of the national drug situation
In order to streamline and effectively control compounding of medicinal products in hospitals and pharmacies, these Guidelines for Production of Extemporaneous and Hospital Based Sterile Preparations has been crafted. The purpose of these guidelines therefore is to assist pharmacists in ...discharging their legal and professional obligations to patients in the area of extemporaneous dispensing. This guidance will help to assure the safe and appropriate preparation and supply of extemporaneously prepared medicinal products to patients, where
the supply of such products is necessary.
Extemporaneous and hospital based sterile preparations are critical for patients whose clinical needs cannot be met by registered medicinal products. The guidelines outline the principles and application of the concepts of Good Manufacturing Practice (GMP) requirements for premises, equipment, personnel, storage, quality management system, quality control, compounding processes as well as documentation.
more
1 billion people are at risk of infection with leishmaniasis, a neglected disease strongly linked to poverty. There’s no single, simple cure: current treatments are complex and need to be adapted to the form of the disease and geographical region.
Информация для пострадавших и их близких. В нашей работе мы постоянно сталкиваемся с просьбами написать руководство, как вести себя после травматического опыта. П...страдавшим хотелось бы почитать такую информацию, их близкие ищут материалы, которые помогли бы им понять пострадавших.
more
Leishmaniasis is among the most neglected diseases. The most common form is cutaneous leishmaniasis that forms lesions on the skin.
The only treatment available for cutaneous leishmaniasis is highly toxic. In some cases, patients have died because of the treatment, even though cutaneous leishmania...sis is not fatal.
more
Травма – що робити
Щоби Ви більше не відчували себе такими безпорадними
Інформація для постраждалих людей та їхніх близьких
Ukrainische Ausgabe der Broschüre:
Trauma – was tun? Damit Sie ...sich nicht mehr so hilflos fühlen müssen. Informationen für akut betroffeneMenschen und deren Angehörige
more